{"id":175292,"date":"2023-07-27T00:00:00","date_gmt":"2023-07-26T22:00:00","guid":{"rendered":"https:\/\/www.bcfi.be\/daclizumab-zinbryta-stand-van-zaken-5-jaar-na-commercialisering\/"},"modified":"2026-04-02T19:09:13","modified_gmt":"2026-04-02T17:09:13","slug":"daclizumab-zinbryta-stand-van-zaken-5-jaar-na-commercialisering","status":"publish","type":"post","link":"https:\/\/www.bcfi.be\/nl\/daclizumab-zinbryta-stand-van-zaken-5-jaar-na-commercialisering\/","title":{"rendered":"Daclizumab (Zinbryta\u00ae): stand van zaken 5 jaar na commercialisering"},"content":{"rendered":"<div class='summary'>Daclizumab (Zinbryta&reg;) werd 5 jaar geleden gecommercialiseerd met als indicatie de behandeling van <i>relapsing-remitting<\/i> multiple sclerose. Deze IL-2 receptor antagonist werd in 2018 door de firma van de markt gehaald nadat het Europees geneesmiddelenagentschap een <a href='https:\/\/www.ema.europa.eu\/en\/news\/ema-recommends-immediate-suspension-recall-multiple-sclerosis-medicine-zinbryta'>dringende evaluatie<\/a> had opgestart omwille van een risico van encefalitis en meningo-encefalitis.<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Daclizumab (Zinbryta&reg;) werd 5 jaar geleden gecommercialiseerd met als indicatie  [&#8230;]<\/p>\n","protected":false},"author":9,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[43,14916],"tags":[20213,20224],"class_list":["post-175292","post","type-post","status-publish","format-standard","hentry","category-nieuw","category-2023-nl","tag-import_tags","tag-import_tags-nl"],"_links":{"self":[{"href":"https:\/\/www.bcfi.be\/nl\/wp-json\/wp\/v2\/posts\/175292","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.bcfi.be\/nl\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.bcfi.be\/nl\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.bcfi.be\/nl\/wp-json\/wp\/v2\/users\/9"}],"replies":[{"embeddable":true,"href":"https:\/\/www.bcfi.be\/nl\/wp-json\/wp\/v2\/comments?post=175292"}],"version-history":[{"count":1,"href":"https:\/\/www.bcfi.be\/nl\/wp-json\/wp\/v2\/posts\/175292\/revisions"}],"predecessor-version":[{"id":177874,"href":"https:\/\/www.bcfi.be\/nl\/wp-json\/wp\/v2\/posts\/175292\/revisions\/177874"}],"wp:attachment":[{"href":"https:\/\/www.bcfi.be\/nl\/wp-json\/wp\/v2\/media?parent=175292"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.bcfi.be\/nl\/wp-json\/wp\/v2\/categories?post=175292"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.bcfi.be\/nl\/wp-json\/wp\/v2\/tags?post=175292"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}